Delivery Order SPE2DB24D2205-SPE2DB26FDSSF
- Not listed
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp on June 20, 2025, for the supply of Vyndamax 61 mg capsules in unit dose packaging (30-count). The contract, which is not set-aside and carries a firm fixed price structure, is scheduled for ultimate completion by July 14, 2025. Performance will be executed from the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsules (30-count unit dose packaging) with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract is classified as a non-set-aside and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsule unit dose packages (30-count) on September 18, 2025, with completion scheduled for October 9, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count) with a firm fixed price structure. The contract, which is not set-aside, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 30, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $27,693.94 delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsule unit dose packages (30-count) on September 11, 2025, with an ultimate completion date of October 2, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The vendor, headquartered in Conshohocken, Pennsylvania, will perform at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Vyndamax 61 mg capsules in unit dose packages of 30 units. This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 18, 2025, to be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $55,387.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages in quantities of 30. The contract, which represents a non-competitive set-aside award, is scheduled for completion by October 14, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania location. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyndamax 61 mg capsules in unit dose packages of 30 count. This is a firm fixed price delivery order with a ceiling value of $27,693.94 and an ultimate completion date of September 16, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $13,846.97 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsules (unit dose, 30-count packages) on September 11, 2025, with an ultimate completion date of October 2, 2025. This non-set-aside competitive award represents a child delivery order against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December...
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Vyndamax 61 mg capsules in unit dose packaging (30-count). This is a firm fixed price delivery order with an ultimate completion date of July 11, 2025, and no set-aside designation was used in the competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB26FDSSFDelivery Order
The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count). The contract is competitively awarded with no set-aside designation and carries a firm fixed price structure, with an ultimate completion date of November 14, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical supply vehicle enabling the company to deliver a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. The current delivery order for Vyndamax, a medication used to treat transthyretin (TTR) amyloidosis, reflects the company's role as a critical pharmaceutical vendor serving the Defense Health Agency and other federal healthcare systems through this flexible contracting mechanism.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.8k | 10/23/25 |